PARADIGM BIOPHARMACEUTICALS SPOTLIGHTS POTENTIAL BREAKTHROUGH OSTEOARTHRITIS TREATMENT AT BIOLOGICAL ASSOCIATION 3RD ANNUAL SUMMIT

PARADIGM BIOPHARMACEUTICALS SPOTLIGHTS POTENTIAL BREAKTHROUGH OSTEOARTHRITIS TREATMENT AT BIOLOGICAL ASSOCIATION 3RD ANNUAL SUMMIT

May 24, 2022 by PR Newswire

Key Facts

  • , /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a clinical-stage biopharmaceutical company focused on repurposing existing molecules for new indications with unmet clinical needs, is honored that its Global Clinical Head of Osteoarthritis (OA) Mukesh Ahuja was selected to speak at the Biological Association 3rd Annual Summit, held in conjunction with the 2022 Arthroscopy Association of North America (AANA) Annual Meeting, in San Francisco.
  • "Paradigm recognizes the pressing need for new, safe, and effective treatments for the pain and symptoms of OA, and we hope that PPS has the potential to be a powerful candidate in this field.
  • About Paradigm Biopharmaceuticals Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialize pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection, or genetic predisposition.
  • In addition to the OA program, Paradigm is currently conducting two phase II studies for the use of iPPS as adjunct therapy to help manage residual musculoskeletal symptoms despite enzyme replacement therapy or haemopoietic stem cell transplant in the rare diseases mucopolysaccharidosis type I, and mucopolysaccharidosis type VI.

Click To Read Full Article

EVENT
GEOGRAPHY
PERSON
ORGANIZATION
MISCELLANEOUS

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?